A new AI start­up, launched with a trio of Fred Hutch vets, wants to give a 'zoomed-in' view of can­cer cells

3 years ago
Financing
AI

Dana-Far­ber CEO Lau­rie Glim­ch­er re­signs from GSK board — is she the next NIH di­rec­tor nom­i­nee?

3 years ago
People
Pharma

For­mer eGe­n­e­sis CEO joins vTv as it tries to make a come­back; Ei­sai nabs Alzheimer’s com­mer­cial ex­ec amid lecanemab ...

3 years ago
Peer Review

By ex­ploit­ing the DNA re­pair sys­tem, Yale sci­en­tists want to crack chemother­a­py re­sis­tant brain can­cer

3 years ago
R&D

On heels of record-break­ing Q2, Pfiz­er CEO Al­bert Bourla out­lines plans to ‘go very big’ on BD

3 years ago
Pharma

UK-based Ab­b­Vie sales rep rais­es con­cerns about 's­trate­gic loi­ter­ing' out­side hos­pi­tals dur­ing the pan­dem­ic

3 years ago
Pharma

Paul Hud­son: Sanofi 'least ex­posed' to gener­ic com­pe­ti­tion as Big Phar­ma dou­bles down on Dupix­ent

3 years ago
Pharma

Graphite Bio de­buts cor­po­rate brand cam­paign with ‘Cure’ as­pi­ra­tions, even years ahead of drug ap­proval

3 years ago
Pharma
Marketing

Sen­ate pro­pos­es $16B to fund the next wave of Covid-19 vac­cines, ther­a­peu­tics in 2023

3 years ago
FDA+
Coronavirus

Man­u­fac­tur­ing roundup: Gen­Bio­Pro looks to counter Mis­sis­sip­pi trig­ger law; Pis­gah Labs to in­vest $55M in NC ex­pan­sion ...

3 years ago
Manufacturing

Af­ter net­ting $200M, Syn­thego to break ground on its man­u­fac­tur­ing fa­cil­i­ty

3 years ago
Cell/Gene Tx
Manufacturing

PCI Phar­ma com­mits to a mul­ti­mil­lion-dol­lar ex­pan­sion of its man­u­fac­tur­ing fa­cil­i­ty in Wales

3 years ago
Pharma
Manufacturing

David Li­u's lab de­vel­ops next-gen base ed­i­tors, small enough to fit in­to sin­gle AAV

3 years ago
R&D
Discovery

Io­n­is, Cy­cle­ri­on tout pos­i­tive da­ta read­outs; MA­IA prices first biotech IPO in over two months

3 years ago
News Briefing

El­e­va­tion On­col­o­gy dips its toes in­to AD­Cs, adding sec­ond drug to its bag. But is it pit­ting it­self against Bris­tol ...

3 years ago
R&D

What can Mer­ck af­ford to buy now? ‘ANY­THING’ it wants

3 years ago
Deals
Bioregnum

Small Penn­syl­va­nia biotech lays off a fourth of its staff as it tries to nav­i­gate com­mer­cial land­scape

3 years ago
People

Take­da ax­es clin­i­cal-stage pro­gram in $1B+ Turn­stone Bi­o­log­ics col­lab­o­ra­tion

3 years ago
Pharma

Lex­i­con hops on pub­lic of­fer­ing train to pre­pare for next year's po­ten­tial drug ap­proval

3 years ago
Financing

Two groups look to bring stan­dard­iza­tion to cell ther­a­py man­u­fac­tur­ing in their lat­est pa­per

3 years ago
Manufacturing

Up­dat­ed: Deep­Mind's Al­phaFold now con­tains struc­ture of 200M pro­teins. What does that mean for drug R&D?

3 years ago
R&D
AI

Lab­corp is spin­ning out its clin­i­cal de­vel­op­ment unit in ma­jor shake­up

3 years ago
Deals
Manufacturing

'Tip of the ice­berg': No­var­tis-part­nered UC Berke­ley lab churns out a start­up to tack­le pro­tein sta­bi­liza­tion

3 years ago
Financing
Startups

Manchin strikes again: Rec­on­cil­i­a­tion pack­age sur­faces, with drug pric­ing re­forms ful­ly in­tact — for now

3 years ago
Pharma
Law
First page Previous page 488489490491492493494 Next page Last page
A service from the Financial Times